Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability.
Details
Serval ID
serval:BIB_28B2927C0A6D
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability.
Journal
Clinical microbiology and infection
Working group(s)
VEBCON, VSV-EBOVAC, VSV-EBOPLUS Consortia
Contributor(s)
Agnandji S.T., Krishna S., Kremsner P.G., Brosnahan J.S., Addo M.M., Becker S., Kra Hling V., Bejon P., Njuguna P., Siegrist C.A., Huttner A., Kieny M.P., Moorthy V., Fast P., Savarese B., Lapujade O., Agnandji S.T., Ahmed R., Anderson J., Auderset F., Bejon P., Borgianni L., Brosnahan J., Ciabattini A., Engler O., Haks MLC, Harandi A., Heppner D.G., Gerlini A., Huttner A., Kremsner P.G., Medaglini D., Monath T., Ndungu F., Njuguna P., Ottenhoff T.H., Pejoski D., Page M., Pozzi G., Santoro F., Siegrist C.A., Agnandji S.T., Auderset F., Borgianni L., Dubey S., Engler O., Fernandes J.F., Haks MLC, Harandi A., Gerlini A., Huttner A., Kremsner P.G., Lucchesi S., Medaglini D., Monath T., Nakaya H., Nakka S.S., Orourke F., Ottenhoff T.H., Pejoski D., Pozzi G., Rothenberger S., Santoro F., van Veen S., Vianello E., Siegrist C.A.
ISSN
1469-0691 (Electronic)
ISSN-L
1198-743X
Publication state
Published
Issued date
12/2023
Peer-reviewed
Oui
Volume
29
Number
12
Pages
1587-1594
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Abstract
To report 5-year persistence and avidity of antibodies produced by the live-attenuated recombinant vesicular stomatitis virus (rVSV) expressing the Zaire Ebolavirus (ZEBOV) glycoprotein (GP), known as rVSV-ZEBOV (Ervebo®).
Healthy adults vaccinated with 300,000 or 10-50 million plaque-forming units of rVSV-ZEBOV in the WHO-coordinated trials of 2014-2015 were followed for up to 4 (Lambaréné, Gabon) and 5 (Geneva, Switzerland) years. We report seropositivity rates, geometric mean titres (GMTs), and population distribution of ZEBOV-GP ELISA IgG antibodies, neutralizing antibodies (pseudovirus and live-virus neutralization) and antibody avidity; the primary outcome was ZEBOV-GP ELISA IgG GMTs at 4 or 5 years compared with 1 year (Y1) after immunization.
Among the 168 eligible vaccinees (Geneva: 97 and Lambaréné: 71) enrolled 1 year post-immunization, 146 (87%) remained enrolled at 4 years (Geneva: n = 88, Lambaréné: n = 58), and 84 (87%, Geneva) at 5 years post-vaccination. ZEBOV-GP ELISA IgG GMTs plateaued, with no declining trend from 1 year through the last time point assessed (1147.8 [95% CI 874.3-1507.0] at Y1 versus 1548.1 [95% CI 1136.6-2108.5] at Y5 in Geneva volunteers receiving ≥10 million plaque-forming units of rVSV-ZEBOV), their avidity matching that of ZEBOV convalescents. Live-virus neutralizing antibodies were detected for shorter periods and in fewer vaccinees (53/95 [56%] at Y1 versus 35/84 [42%] at Y5 in Geneva volunteers, all dose levels).
Titres at Y1 emerged as a correlate of antibody persistence at Y5. The findings of persistent ZEBOV-GP ELISA IgG titres yet shorter-lasting, lower titres of live-virus neutralizing antibodies suggest the contribution of antibody-mediated protective mechanisms other than neutralization. Long-term clinical efficacy of rVSV-ZEBOV, however, requires further study.
Healthy adults vaccinated with 300,000 or 10-50 million plaque-forming units of rVSV-ZEBOV in the WHO-coordinated trials of 2014-2015 were followed for up to 4 (Lambaréné, Gabon) and 5 (Geneva, Switzerland) years. We report seropositivity rates, geometric mean titres (GMTs), and population distribution of ZEBOV-GP ELISA IgG antibodies, neutralizing antibodies (pseudovirus and live-virus neutralization) and antibody avidity; the primary outcome was ZEBOV-GP ELISA IgG GMTs at 4 or 5 years compared with 1 year (Y1) after immunization.
Among the 168 eligible vaccinees (Geneva: 97 and Lambaréné: 71) enrolled 1 year post-immunization, 146 (87%) remained enrolled at 4 years (Geneva: n = 88, Lambaréné: n = 58), and 84 (87%, Geneva) at 5 years post-vaccination. ZEBOV-GP ELISA IgG GMTs plateaued, with no declining trend from 1 year through the last time point assessed (1147.8 [95% CI 874.3-1507.0] at Y1 versus 1548.1 [95% CI 1136.6-2108.5] at Y5 in Geneva volunteers receiving ≥10 million plaque-forming units of rVSV-ZEBOV), their avidity matching that of ZEBOV convalescents. Live-virus neutralizing antibodies were detected for shorter periods and in fewer vaccinees (53/95 [56%] at Y1 versus 35/84 [42%] at Y5 in Geneva volunteers, all dose levels).
Titres at Y1 emerged as a correlate of antibody persistence at Y5. The findings of persistent ZEBOV-GP ELISA IgG titres yet shorter-lasting, lower titres of live-virus neutralizing antibodies suggest the contribution of antibody-mediated protective mechanisms other than neutralization. Long-term clinical efficacy of rVSV-ZEBOV, however, requires further study.
Keywords
Adult, Animals, Humans, Hemorrhagic Fever, Ebola, Ebolavirus/genetics, Antibody Formation, Democratic Republic of the Congo, Ebola Vaccines, Vesicular Stomatitis, Antibodies, Viral, Vaccination, Antibodies, Neutralizing, Immunoglobulin G, Antibodies, Blocking, Antibody avidity, Antibody persistence, Ebola virus disease, Immunogenicity, Neutralizing antibodies, Vaccine
Pubmed
Web of science
Open Access
Yes
Create date
13/09/2023 15:39
Last modification date
13/01/2024 7:08
Usage data
